<DOC>
	<DOCNO>NCT02455011</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind , dose escalation study evaluate safety , tolerability , PK PD single repeat SC dose REMD-477 Type 2 diabetic subject . The study conduct multiple site United States enroll approximately 102 subject Type 2 diabetes either treatment-naïve , control diet exercise treat oral antidiabetic medication .</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics REMD-477 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study consist three part : Part A - Dose Escalation , Part B - Adaptive Dose Cohort , Part C - REMD-477 Combination Metformin . Part A include 5 cohort enrol dose sequentially escalate dos . Each cohort consist 12 subject randomize 3:1 ( active : placebo ) fashion . Part B include single dose cohort enroll 12 subject ( 9 active treatment 3 placebo ) dose level frequency determine Dose Level Review Meeting ( DLRM ) Committee . Part C include 2 cohort T2DM patient currently treat metformin alone , cohort consist 15 subject ( 10 active treatment 3 placebo ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Men woman age 18 65 year old , inclusive , time screening ; Females nonchild bear potential must ≥1 year postmenopausal ( confirm serum folliclestimulating hormone ( FSH ) level ≥ 40 IU/mL ) document surgically sterile , female child bear potential must use two medically acceptable method contraception ; Male subject must willing use clinically acceptable contraception treatment 2 month last administration REMD477 ; Normal clinicallyacceptable physical examination , laboratory test value , 12lead ECG ( report heart rate PR , QRS , QT , QTcF ) screening ; Body mass index 23 40 kg/m2 , inclusive , screen ; Diagnosed Type 2 diabetes define current American Diabetes Association ( ADA ) criterion ; Subjects Parts A B : Treatmentnaive , control diet exercise , treat oral antidiabetic medication willing washout discontinue oral medication study ; Fasting plasma glucose 126 270 mg/dL ( 715 mM ) , inclusive , screen retest Day 1 ; Subjects Parts A B : Screening HbA1c 7.010 % inclusive subject currently take oral antidiabetic medication , 6.59.5 % subject receive acceptable oral antidiabetic medication ; Subjects Part C : Screening HbA1c 7.510 % inclusive subject stable dos metformin . History drug alcohol abuse within last 6 month positive illegal drug urine test result ; History family history pancreatic neuroendocrine tumor multiple endocrine neoplasia ; History family history pheochromocytoma ; Known suspect susceptibility infectious disease ( eg , take immunosuppressive agent document inherited acquire immunodeficiency ) ; Positive human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody ( HepC Ab ) ; Participation investigational drug device trial within 30 day screen within 5 time halflife investigational agent clinical study , know , whichever period longer ; Blood donor , blood loss &gt; 300 mL , within 30 day Day 1 ; Recent use ( 6 week prior Screening ) thiazolidinediones , &gt; halfmaximal dose sulfonylurea agent therapy , injectable antidiabetic agent ( exenatide injectable GLP1 agonist , insulin insulin analog , etc . ) ; Other gastrointestinal , cardiac , renal CNS ( i.e . hypoglycemia unawareness ) condition specific diabetes would pose additional risk subject 's safety interfere study evaluation , procedures completion ; Lipid panel profile nonHDLC ( total cholesterol minus HDLC ) &gt; 219 mg/dL , LDLC &gt; 189 mg/dL , and/or fast triglyceride &gt; 499 mg/dL ; Female subject pregnant breastfeeding . Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>